Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?

Effects of pirfenidone on vital capacity (VC) at week 52 in a Japanese phase III trial. The last observation carried forward method was used for drop-outs in each group. Data are presented as mean±se. Placebo group: n = 103; high-dose group: n = 104; low-dose group: n = 54. ^#: p<0.1, comparison of adjusted means based on ANCOVA (negative and positive of the changes represent deterioration and improvement from baseline, respectively). Reproduced from [31].

Change in forced vital capacity (FVC) % predicted (% pred) in study 004 and study 006 comparing pirfenidone or placebo in patients with idiopathic pulmonary fibrosis [29, 35]. ▪: study 004 pirfenidone 2,403 mg·day⁻¹; •: study 006 pirfenidone 2,403 mg·day⁻¹; ▴: study 006 placebo; ▾: study 004 placebo.

Temporal analysis of change in forced vital capacity per cent predicted with pirfenidone in patients with idiopathic pulmonary fibrosis [34].

Exploratory pooled analysis (studies 004 and 006 combined) of change in forced vital capacity (FVC) with pirfenidone 2,403 mg·day⁻¹ (□: n = 345) or placebo (▪: n = 347) in patients with idiopathic pulmonary fibrosis [29, 35]. ^#: p = 0.005, rank ANCOVA (pirfenidone 2,403 mg·day⁻¹ versus placebo at week 72).

Exploratory pooled analysis (studies 004 and 006 combined) of a) categorical forced vital capacity change at week 72 and b) 6-min walk test distance decrement >50 m (p = 0.03 Cochran–-Haenszel row mean score test based on five categories) [28, 31]. ▒: pirfenidone 2,403 mg·day⁻¹ (n = 345); ░: placebo (n = 347). *: p<0.05; ^#: p = 0.003; ^¶: p≤0.001.